Share Twitter LinkedIn Facebook Email Shyamala Navada, MD of @MountSinaiNYC discusses the phase II study of oral rigosertib combined with azacitidine as first line therapy in patients with HR-MDS.
Cell Therapy for Solid Tumors: Immunotherapy Biomarkers Anusha Kalbasi, MD MOASC [2023] Immunotherapy 2 Mins Read
